(RTTNews) - AbbVie Inc. (ABBV), Wednesday announced Health Canada has issued a Notice of Compliance for RINVOQ for the treatment of adults with giant cell arteritis, both used in combination with a ...

Cosentyx missed primary endpoint in GCA trial but reduced steroid use and toxicity compared to placebo. Cosentyx sales rose 16% year over year to $1.5 billion in Q1 2025, driven by demand across ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of ...

5. Positive temporal artery biopsy Biopsy specimen with the artery showing vasculitis characterized by prominence of mononuclear cell infiltration or granulocyte inflammation, often with ...

1. In this randomized trial, upadacitinib dosed at 15mg with a 26-week glucocorticoid taper showed superior efficacy than placebo with a 52-week glucocorticoid taper for sustained remission of giant ...

Please provide your email address to receive an email when new articles are posted on . At the Congress on Controversies in Ophthalmology, Lee and Susan Mollan, MBChB, FRCOphth, PhD, debated this ...

Findings showed 46.4% of patients treated with upadacitinib 15 mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has approved ...

There is an unmet need for effective, glucocorticoid-sparing treatments for patients with giant-cell arteritis. New research findings on the JAK-1 inhibitor upadacitinib in these patients are ...

Patients presenting with isolated extracranial manifestations of giant cell arteritis represent a distinct phenotype that is associated with younger age at diagnosis and more frequent polymyalgia ...